Scotland’s approval of PrEP creates postcode lottery in UK, say campaigners
BMJ 2017; 357 doi: https://doi.org/10.1136/bmj.j1834 (Published 11 April 2017) Cite this as: BMJ 2017;357:j1834- Bryan Christie
- Edinburgh
Demand is mounting for UK-wide access to pre-exposure prophylaxis (PrEP) to help prevent the transmission of HIV, after it was approved for use on the NHS in Scotland.
Campaigners welcomed the Scottish Medicines Consortium’s (SMC) decision to make Scotland the first part of the UK to approve emtricitabine/tenofovir disoproxil (Truvada) for use on a preventive basis by people without HIV.
PrEP has been shown to be 86% effective in preventing transmission if taken as prescribed and is currently available in Canada, France, Kenya, Norway, and the US. Preventing infection can save an estimated £360 000 (€422 000; $447 000) a patient, which is the …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.